[August 22, 2017]

Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2017 - Research and Markets

The "Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

The latest report provides comprehensive information on the therapeutics under development for Spinal Muscular Atrophy (SMA (News - Alert)) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC (News - Alert) filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Companies Mentioned

• AveXis Inc
• Biogen Inc
• Cytokinetics Inc
• F. Hoffmann-La Roche Ltd
• Genethon SA
• Genzyme Corp
• Kowa Company Ltd
• Neurotune AG
• Novartis AG
• Paratek Pharmaceuticals Inc
• Recursion Pharmaceuticals Inc
• Sarepta Therapeutics Inc
• Scholar Rock Inc
• Spotlight Innovation Inc
• Translate Bio Inc
• WAVE (News - Alert) Life Sciences Ltd

• The pipeline guide provides a snapshot of the global therapeutic landscape of Spinal Muscular Atrophy (SMA) (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Spinal Muscular Atrophy (SMA) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Spinal Muscular Atrophy (SMA) (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Spinal Muscular Atrophy (SMA) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Spinal Muscular Atrophy (SMA) (Central Nervous System)
  

For more information about this report visit https://www.researchandmarkets.com/research/5sbs25/spinal_muscular

View source version on businesswire.com: http://www.businesswire.com/news/home/20170822005625/en/

[ Back To TMCnet.com's Homepage ]